Peter Miles Irving

机构：King's College London, Guy's and St Thomas' NHS Foundation Trust · ORCID：0000-0003-0972-8148

发表论文 701 篇 · 总被引 20359 次 · h-index 75

代表论文

• Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials (2024 · Clinical Gastroenterology and Hepatology · 被引 54)
• Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study (2024 · Inflammatory Bowel Diseases · 被引 29)
• DOP097 Emulsifier restriction is an effective therapy for active Crohn’s disease: the ADDapt trial - a multi-centre, randomised, double-blind, placebo-controlled, re-supplementation trial in 154 patients (2025 · Journal of Crohn s and Colitis · 被引 16)
• Stem Cells and Stem Cell-Derived Factors for the Treatment of Inflammatory Bowel Disease with a Particular Focus on Perianal Fistulizing Disease: A Minireview on Future Perspectives (2024 · BioDrugs · 被引 14)
• Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis (2025 · BMJ Open Gastroenterology · 被引 11)
• DOP056 TDM-Based Dose-Intensification of Infliximab is not Superior to Standard Dosing in Patients with Acute Severe Ulcerative Colitis: Results from the TITRATE Study (2025 · Journal of Crohn s and Colitis · 被引 11)